title: [Immunologic response to antiretroviral treatment with combined stavudine, didanosine and nevirapine].
abstract: OBJECTIVE
  The purpose of this study was to investigate the restoration of immune function in patients given two nucleoside-analogs and one non-nucleoside-analog (nevirapine).
  
  
  METHODS
  The study was carried out in 27 HIV-1-infected patients, starting a treatment with d4T, ddl and nevirapine, included in the VIRGO trial and followed up to 52 weeks.
  
  
  RESULTS
  Total CD4 T cells increased as early as the fourth week of treatment (+154/microliter, p < 0.001) with a gain maintained until week 52 (+201/microliter at week 52). A similar pattern was seen for memory CD4 T cells (+80/microliter at week 4, +110/microliter at week 52). The rise in naive CD4 T cells was slower, strongly significant for week 16 (p < 0.001) and maximum at week 24 (+105/microliter).
  
  
  CONCLUSIONS
  In our study, rise in T cells was not correlated with virological response, however increase in total and naive CD4 T cells was correlated with the CD4 count at onset of therapy (p < 0.05). Our data indicate that patients on d4T-ddl-nevirapine therapy have the same immune restoration as patients given protease inhibitor-based regimens.
authors.affiliation: Laboratoire d'Immunologie, 9, quai Moncousu, F44093 Nantes.
authors.forename: V
authors.initials: V
authors.lastname: Reliquet
authors.forename: N
authors.initials: N
authors.lastname: Robillard
authors.forename: P
authors.initials: P
authors.lastname: Perré
authors.forename: J Y
authors.initials: JY
authors.lastname: Muller
authors.forename: F
authors.initials: F
authors.lastname: Raffi
authors.forename: M
authors.initials: M
authors.lastname: Audrain
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D007156:Immunologic Memory / Q000187:drug effects; D018655:Lymphocyte Count; D008297:Male; D019829:Nevirapine / Q000008:administration & dosage* / Q000009:adverse effects; D010865:Pilot Projects; D018119:Stavudine / Q000008:administration & dosage* / Q000009:adverse effects; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D019829:Nevirapine; D018119:Stavudine; D016049:Didanosine
vernacular_title: Réponse immunologique sous traitement antirétroviral associant stavudine, didanosine et névirapine.